MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cox, R. F.
Right arrow Articles by Waszczak, B. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cox, R. F.
Right arrow Articles by Waszczak, B. L.

Differences in dopamine receptor reserve for N-n-propylnorapomorphine enantiomers: single unit recording studies after partial inactivation of receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline

RF Cox and BL Waszczak

Pharmacology Section, Northeastern University, College of Pharmacy, Boston, Massachusetts 02115.

Previous studies with (S)-(+)-N-n-propylnorapomorphine (NPA), an enantiomer of the potent dopaminergic agonist (R)-(-)-NPA, showed that this compound had a complex pharmacological profile. For example, (S)- (+)NPA had weak dopaminergic agonist potency, in that it could slow and ultimately stop firing of substantia nigra and ventral tegmental area dopamine neurons. However, antagonist properties were also evident inasmuch as immediate pretreatment with a low dose of (S)-(+)-NPA caused a significant rightward shift of the (R)-(-)-NPA dose-response curve. This dual agonist-antagonist nature of (S)-(+)-NPA suggested a low intrinsic efficacy for (S)-(+)-NPA. To test this hypothesis, we conducted dose-response studies for the inhibition of rat substantia nigra dopamine cell firing by (R)-(-)- and (S)-(+)-NPA 1 day after partial irreversible dopamine receptor inactivation with 6 mg/kg N- ethoxycarbonyl-2-ethoxy-1-2-dihydroquinoline (EEDQ) in an ethanol vehicle. This degree of inactivation resulted in a significant, parallel, rightward shift of the (R)-(-)-NPA dose-response curve relative to ethanol-treated control rats, with no loss of maximal response. After pretreatment with the same dose of EEDQ, however, the maximal response to (S)-(+)-NPA was reduced by 22% with no shift on the dose axis. The dose-response curves for control and EEDQ-treated groups were subjected to Furchgott analysis to determine per cent response versus fractional occupancy relationships for each drug. A steep hyperbolic relationship was revealed for (R)-(-)-NPA. Fifty per cent and maximal (greater than 95%) inhibitions of cell firing occurred at 3.5% and approximately 32% receptor occupancies, respectively. Hence, for (R)-(-)-NPA there is about a 68% receptor reserve in this model. The same analysis for (S)-(+)-NPA yielded an occupancy versus response plot that was more shallow and linear. Half-maximal effects occurred at 66% occupancy and the maximal response (96% inhibition) required 94% occupancy, indicating few spare receptors for (S)-(+)-NPA. Because the ratio of fractional occupancies at a given level of response is a measure of relative efficacy, we calculated a relative efficacy of (S)- (+)- to (R)-(-)-NPA of 0.05 (at the 50% response level). This confirms that (S)-(+)-NPA indeed has a much lower intrinsic efficacy than the (R)-(-)-antipode and may account for the previously reported antagonist property of the (+)-form under certain treatment conditions.

Volume 35, Issue 1, pp. 125-131, 01/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
D. M. Mottola, J. D. Kilts, M. M. Lewis, H. S. Connery, Q. D. Walker, S. R. Jones, R. G. Booth, D. K. Hyslop, M. Piercey, R. M. Wightman, et al.
Functional Selectivity of Dopamine Receptor Agonists. I. Selective Activation of Postsynaptic Dopamine D2 Receptors Linked to Adenylate Cyclase
J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 1166 - 1178.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1989 by the American Society for Pharmacology and Experimental Therapeutics